# A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

> **NCT04398108** · PHASE1 · COMPLETED · sponsor: **Zai Lab (Shanghai) Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- HER2 Positive Metastatic Breast Cancer

## Interventions

- **DRUG:** Margetuximab Margetuximab-IV

## Key facts

- **NCT ID:** NCT04398108
- **Lead sponsor:** Zai Lab (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-25
- **Primary completion:** 2021-04-27
- **Final completion:** 2021-04-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04398108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04398108, "A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04398108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*